New hope for bladder cancer: drug combo aims to shrink tumors when first treatment fails

NCT ID NCT07261592

Not yet recruiting Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of the drug entinostat plus standard chemotherapy for people with advanced bladder cancer that has spread or cannot be removed by surgery and has not responded to first-line treatment. About 29 participants will receive the combination to see if it can shrink tumors and control the disease. The goal is to find a better second-line option for this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER CHEMOTHERAPY ENTINOSTAT HISTONE DEACETYLASE INHIBITOR

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University

Nanjing, Jiangsu, 210008, China